Faculty Opinions recommendation of The Rotterdam criteria for polycystic ovary syndrome: evidence-based criteria?

Author(s):  
Fernando Reis
2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Deng Yan ◽  
Wang Yan-Fang ◽  
Zhu Shi-Yang ◽  
Ma Rui-Lin ◽  
Ding Xue-Song ◽  
...  

Abstract Background To describe the diagnostic criteria used and their application accuracy in the practice of polycystic ovary syndrome (PCOS) caring among obstetricians and gynaecologists across China. Methods This was an Online cross-sectional survey of Obstetricians and gynecologists involved in PCOS caring conducted via the largest continuing education platform of obstetrics and gynecology across China from September 2019 to November 2019. Results A total of 2,328 respondents were eligible for the final analysis. Of these, 94.5 % were general obstetricians and gynaecologists (Ge-ObGyn), and 5.5 % were reproductive endocrinologists (Re-ObGyn). Overall, the most frequently used criteria were the Androgen Excess and Polycystic Ovary Syndrome Society (AE-PCOS) criteria (48.2 %), followed by the Rotterdam criteria (35.7 %) and NIH criteria (12.1 %). Of the respondents, 31.3 % used their diagnostic criteria in their clinical practice. More respondents who chose the Rotterdam criteria could accurately apply the diagnostic criteria than those who chose the AE-PCOS criteria (41.2 % vs. 32.1 %, P < 0.001). Compared with Ge-ObGyn, Re-ObGyn were less likely to use the AE-PCOS criteria (adjusted odds ratio, 0.513; 95 % CI, 0.328–0.802; P < 0.05) and 1.492 times more likely to accurately use their criteria (95 % CI, 1.014–2.196; P < 0.05). Conclusions Less than one-third of obstetricians and gynaecologists across China could accurately use the diagnostic criteria they choose to diagnose PCOS. There is an urgent need to train obstetricians and gynaecologists on PCOS diagnosis in an effort to improve the medical care quality of patients with PCOS.


Author(s):  
Shivani Yadav ◽  
Srishti Tripathi ◽  
Soumya Agarwal ◽  
Titiksha Hans ◽  
Anshul Choudhary ◽  
...  

Background: According to Global Burden of Skin Disease study data, 2013, Acne affects nearly 85% of adolescents and young adults in the age group 12-25 years.1 traditionally it was considered to be a transitory disease of teenagers and young adults; however recent study reports indicate it to be a disease affecting all age groups in adults. Aims: To study the clinical profile of adult acne, grade the severity using global acne grading system (GAGS) and to determine the proportion of Polycystic Ovary Syndrome (PCOS) in women with adult acne. Material and Methods: Patients with acne in the age group of 25-60 years were included in the study. A detailed examination of clinical profile of acne was done along with grading of severity of acne using GAGS. Also, documentation of hyperandrogenism using Ferriman Gallwey score for hirsutism and diagnosis of PCOS using Rotterdam criteria was done in all female patients of acne. Results: A total of 105 patients were included in the study. Among these, 82.9% were women and 17.1% were men. The mean age of the patients was 28.04±3.60 years. Persistent acne was observed in 85.7%, while late onset in 14.3%. Most common site of involvement was cheek (98%), followed by chin (76%), and forehead (64.7%). Mild grade acne was observed in 93.3% patients. Hyperpigmentation was seen in 78.1% while scarring was observed in 52.4% patients. A total of 8% female patients had PCOS according to Rotterdam criteria. Conclusion: We found a predominance of females and persistent acne. Although the prevalence of PCOS was low in adult female acne patients, they were affected by more severe grades of acne and risk of hyperpigmentation and scarring was higher as compared to non-PCOS patients.


2018 ◽  
Vol 89 (3) ◽  
pp. 251-268 ◽  
Author(s):  
Helena J. Teede ◽  
Marie L. Misso ◽  
Michael F. Costello ◽  
Anuja Dokras ◽  
Joop Laven ◽  
...  

Nutrients ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 2711 ◽  
Author(s):  
Annie W. Lin ◽  
Maryam Kazemi ◽  
Brittany Y. Jarrett ◽  
Heidi Vanden Brink ◽  
Kathleen M. Hoeger ◽  
...  

Lifestyle modifications are recommended as first-line therapy in polycystic ovary syndrome (PCOS). However, usual dietary and physical activity (PA) behaviors of women with PCOS remain uncertain, likely owing to controversy in diagnostic criteria. Our objective was to contrast the usual dietary and PA behaviors of women with PCOS (n = 80) diagnosed by the 2018 International Evidence-based Guideline for the Assessment and Management of PCOS to that of controls (n = 44). Study outcomes were dietary intake, diet quality (Healthy Eating Index-2015), and PA (questionnaire, waist-worn accelerometers). Women with PCOS met the acceptable macronutrient distribution ranges for carbohydrate, fat, and protein, but did not meet the recommended dietary reference intakes for vitamin D (mean (95% confidence interval); 6 (5–7) μg/d), vitamin B9 (275 (252–298) μg/d), total fiber (24 (22–26) g/d), or sodium (4.0 (3.6–4.4) g/d). Women with PCOS also met the US recommendations for PA. No differences were detected in dietary intake, diet quality, or PA levels between groups (p ≥ 0.11). In conclusion, women with and without PCOS have comparable dietary and PA behaviors. A lack of unique targets for dietary or PA interventions supports the position of the new guideline to foster healthy lifestyle recommendations for the management of PCOS.


2019 ◽  
Vol 25 (10) ◽  
pp. 1056-1066 ◽  
Author(s):  
Yang Zhao ◽  
Yinlong Zhao ◽  
Chunpeng Wang ◽  
Zhenzhen Liang ◽  
Xin Liu

Objective: A previous meta-analysis carried out on the predictive ability of anti-Müllerian hormone (AMH) for polycystic ovary syndrome (PCOS) showed that independent AMH may be a useful initial diagnostic test for PCOS. The aims of this study were to update the meta-analysis and to evaluate the diagnostic efficacy of AMH when it replaces polycystic ovary morphology (PCOM) in the Rotterdam criteria. Methods: Two independent reviewers searched PubMed, Cochrane Library, and the Web of Science databases systematically to identify relevant articles by using the key words “anti-Müllerian hormone” and “polycystic ovary syndrome.” The deadline for manuscript inclusion was July 31, 2018. A random effects model was used and subgroup analysis and meta regression were performed to identify possible sources of heterogeneity. The methodologic quality of each study was assessed by QUADAS-2 and funnel plot asymmetry test. Results: According to the inclusion criteria, 29 studies were included in this meta-analysis. The pooled sensitivity, specificity, and diagnostic odds ratio (DOR) for AMH alone detecting PCOS were 0.76 (95% confidence interval [CI] 0.71 to 0.81), 0.86 (95% CI 0.82 to 0.90) and 20 (95% CI 12 to 33), respectively. When AMH replaces polycystic ovary morphology (PCOM) for the diagnosis of PCOS, the pooled sensitivity, specificity, and DOR rose to 0.93 (95% CI 0.89 to 0.96), 0.99 (95% CI 0.95 to 1.00), and 1,634 (95% CI 217 to 12,324), respectively. The area under the summary receiver-operating characteristic curve for AMH alone and for AMH replacing PCOM detecting PCOS were 0.88 (95% CI 0.85 to 0.91) and 0.97 (95% CI 0.95 to 0.98), respectively, which was found to be significantly different ( Z = 4.89, P<.01). Conclusion: When AMH replaces PCOM in the Rotterdam criteria, the diagnostic efficacy for polycystic ovary syndrome is better. Abbreviations: AMH = anti-Müllerian hormone; AUC = area under the summary receiver operating characteristic curve; BMI = body mass index; CI = confidence interval; DOR = diagnostic odds ratio; HA = hyperandrogenism; IBC = Immunotech-Beckman Coulter; NLR = negative likelihood ratio; OA = oligo-anovulation; PCOM = polycystic ovary morphology; PCOS = polycystic ovary syndrome; PLR = positive likelihood ratio; QUADAS = the Quality Assessment of Diagnostic Accuracy Studies; SENS = sensitivity; SPEC = specificity


Sign in / Sign up

Export Citation Format

Share Document